Diadia
Our TechnologyResourcesAboutLoginBook a call

© 2026 Diadia. All rights reserved.

About UsOur TechnologyResearchResources
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions
About UsOur TechnologyResearchResources
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions

© 2026 Diadia. All rights reserved.

←Transparency Reports

metabolic · Mechanism Report

Does the MTRR rs1801394 GG genotype raise homocysteine, especially with low vitamin B12?

The MTRR rs1801394 GG genotype is associated with higher homocysteine levels, and this effect is amplified when vitamin B12 status is low.

PlausibleJune 19, 20268 Sources

Reasoning Paths

Each route from condition to outcome carries a support score — the product of its edge weights. Select one to isolate it on the figure.

This is what AI claimed

MTRR rs1801394 (A66G) GG genotype is associated with higher homocysteine, particularly when vitamin B12 status is low.

laying out figure…
1 of 2 paths supported
UnsupportedPlausibleSupported

How to read the figure

Evidence state

  • ●EstablishedStrong, replicated evidence.
  • ◐ModerateEvidence-informed; limited or moderate.
  • ◇PlausibleMechanistically coherent, not established.
  • ✕UnsupportedTested and not supported — link breaks.
  • ?MissingNo evidence either way — untested.

Node shapes

  • BiomarkerA measurable state — a lab value, hormone, or genetic factor.
  • ProcessA biological process, pathway, or mechanism step.
  • ConditionA condition, exposure, intervention, or symptom.
  • OutcomeThe endpoint the claim leads to.

Executive summary

The claim states that the GG homozygous variant of MTRR reduces the enzyme's ability to reactivate cobalamin, impairing remethylation of homocysteine to methionine and leading to elevated homocysteine. The mechanism and evidence indicate the genetic effect is modest at baseline but is substantially exacerbated under low or marginal vitamin B12 status, while adequate B12 largely mitigates the risk.

Verified conclusion

The MTRR rs1801394 (A66G) polymorphism represents a significant genetic modifier of folate and cobalamin (vitamin B12) metabolism, with direct implications for cellular methylation and cardiovascular health.

Mechanistic pathway

  • Methionine synthase reductase (MTRR) is responsible for maintaining the enzyme methionine synthase (MTR) in its active state by regenerating its essential cofactor, methylcobalamin (active vitamin B12).
  • The MTRR rs1801394 (A66G) polymorphism involves an isoleucine-to-methionine substitution at codon 22. The homozygous variant (GG genotype) has a reduced capacity to reactivate cobalamin.
  • When cobalamin reactivation is impaired, the remethylation pathway that converts homocysteine to methionine is compromised, resulting in an accumulation of intracellular and plasma homocysteine.

Clinical evidence and B12 interaction

  • The MTRR rs1801394 GG genotype is associated with a modest but statistically significant increase in baseline plasma homocysteine levels.
  • This genetic impact is highly dependent on systemic micronutrient availability. The risk of hyperhomocysteinemia with the GG genotype is sharply exacerbated under conditions of low or marginal vitamin B12 status.
  • Conversely, when vitamin B12 levels are optimal, the enzyme inefficiency associated with the GG genotype is largely bypassed, normalizing homocysteine levels and mitigating the genetic risk.

Clinical implications for older adults

  • For an older adult, such as a 68-year-old male, monitoring B12 status is particularly crucial because aging-related decreases in gastric acid secretion and intrinsic factor production can impair dietary B12 absorption, compounding this genetic risk.

Bottom line

  • The MTRR rs1801394 GG genotype elevates the risk of higher homocysteine, particularly when vitamin B12 status is low. Ensuring adequate vitamin B12 levels is a highly effective clinical strategy to counteract this genetic predisposition and maintain healthy homocysteine levels.

References

  1. Genetics of homocysteine metabolism and associated disorders. — pmc.ncbi.nlm.nih.gov ↗
  2. Association of MTHFR C677T, MTHFRA1298C and MTRRA66G gene polymorphisms with hyperhomocysteinemia and its modulation by the combined effect of vitamin B12 and folate in a hypertensive Chinese population. — linkinghub.elsevier.com ↗
  3. Association of methionine synthase (rs1805087), methionine synthase reductase (rs1801394), and methylenetetrahydrofolate dehydrogenase 1 (rs2236225) genetic polymorphisms with recurrent implantation failure — tandfonline.com ↗
  4. Defects in homocysteine metabolism: diversity among hyperhomocyst(e)inemias — pmc.ncbi.nlm.nih.gov ↗
  5. The common homocystinuria-associated P1173L variant of human methionine synthase impairs reductive methylation — linkinghub.elsevier.com ↗
  6. When to Measure Plasma Homocysteine and how to Place it in Context: The Homocystinurias — sciendo.com ↗
  7. MTRR rs326119 polymorphism is associated with plasma concentrations of homocysteine and cobalamin, but not with congenital heart disease or coronary atherosclerosis in Brazilian patients — pmc.ncbi.nlm.nih.gov ↗
  8. A transgenic mice model of retinopathy of cblG-type inherited disorder of one-carbon metabolism highlights epigenome-wide alterations related to cone photoreceptor cells development and retinal metabolism — pmc.ncbi.nlm.nih.gov ↗

See a full patient report verified like this

Book a walkthrough

Related Claims

Plausible8 sourcesDoes the MTHFR rs1801131 A1298C variant mildly reduce enzyme activity and have a smaller homocysteine effect than C677T?→Plausible3 sourcesIs TMAO formed from gut microbial conversion of choline and carnitine followed by liver oxidation?→